Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 déc. 2025 08h00 HE | Source: ImmuneWalk Therapeutics, Inc.

ImmuneWalk Therapeutics Announces Positive Results from Phase 1 SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Autoimmune Diseases

Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and Mechanistic ValidationClinical Data Build Upon Robust Preclinical Activity Seen...
11 juin 2025 08h00 HE | Source: ImmuneWalk Therapeutics, Inc.

ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601

Study met primary endpoint of safety and tolerability at all doses and secondary pharmacodynamic and pharmacokinetic endpoints after single subcutaneous administrationPharmacodynamics provides...
07 mai 2025 09h55 HE | Source: ImmuneWalk Therapeutics, Inc.

ImmuneWalk Therapeutics Announces $7 Million Seed Financing and Upcoming Presentations of Positive Clinical Results at Upcoming Medical and Industry Conferences

Completed seed financing round of $7 million from an institutional investor and ImmuneWalk’s management teamIncludes oral presentation of positive safety, pharmacokinetic, and pharmacodynamic data...